标题: |
PARPi相互作用管理专家共识 |
title: |
Expert Consensus on PARPi Interaction Management |
版本: |
原创版 |
version: |
Original |
分类: |
专家共识 |
classification: |
Experts consensus |
领域: |
管理 |
field: |
Administration |
国家和地区: |
中国 |
Country and
region:
|
China |
指南使用者: |
|
Guide users:
|
|
证据分级方法: |
本专家编写组制定 |
Evidence grading
method:
|
Rating system were determined by this expert group |
制定单位: |
浙江省人民医院 |
Formulating unit: |
Zhejiang Provincial People's Hospital |
注册时间: |
2022-09-12 |
Registration time: |
注册编号: |
PREPARE-2022CN596 |
Registration number: |
指南制订的目的: |
大多数PARPi通过肝药酶代谢,和其他药物之间存在广泛的药物相互作用,在临床使用过程中容易被忽视,从而造成毒性增加或疗效下降。本共识系统总结中国上市PARPi的相互作用,形成相关推荐意见,为PARPi临床安全合理使用提供参考。 |
Purpose of the guideline:
|
Most PARPi are metabolized by liver enzymes, and there are extensive drug interactions with other drugs, which are easy to be ignored in clinical use, resulting in increased toxicity or decreased efficacy. This consensus systematically summarizes the interaction of PARPi listed in China and forms relevant recommendations to provide reference for the safe and rational use of PARPi in clinic. |